524 related articles for article (PubMed ID: 33116601)
21. Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes.
Fischel JL; Formento P; Ciccolini J; Etienne-Grimaldi MC; Milano G
Anticancer Drugs; 2004 Nov; 15(10):969-74. PubMed ID: 15514566
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity.
Wang Y; Wang W; Dong H; Wang G; Chen W; Chen J; Chen W
Front Oncol; 2023; 13():1017237. PubMed ID: 36937428
[TBL] [Abstract][Full Text] [Related]
23. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity.
Ma WW; Saif MW; El-Rayes BF; Fakih MG; Cartwright TH; Posey JA; King TR; von Borstel RW; Bamat MK
Cancer; 2017 Jan; 123(2):345-356. PubMed ID: 27622829
[TBL] [Abstract][Full Text] [Related]
24. The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine).
Challoob MA; Mohammed NS
Cureus; 2023 Sep; 15(9):e44534. PubMed ID: 37790008
[TBL] [Abstract][Full Text] [Related]
25. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
26. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Schöffski P
Anticancer Drugs; 2004 Feb; 15(2):85-106. PubMed ID: 15075664
[TBL] [Abstract][Full Text] [Related]
27. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
28. The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes.
Saif MW; Smith M; Maloney A
Cureus; 2016 Sep; 8(9):e783. PubMed ID: 27752409
[TBL] [Abstract][Full Text] [Related]
29. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
[TBL] [Abstract][Full Text] [Related]
30. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.
Pandor A; Eggington S; Paisley S; Tappenden P; Sutcliffe P
Health Technol Assess; 2006 Nov; 10(41):iii-iv, xi-xiv, 1-185. PubMed ID: 17049138
[TBL] [Abstract][Full Text] [Related]
31. TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy.
Yano W; Yokogawa T; Wakasa T; Yamamura K; Fujioka A; Yoshisue K; Matsushima E; Miyahara S; Miyakoshi H; Taguchi J; Chong KT; Takao Y; Fukuoka M; Matsuo K
Mol Cancer Ther; 2018 Aug; 17(8):1683-1693. PubMed ID: 29748212
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
Iqbal S; Lenz HJ
Expert Rev Anticancer Ther; 2004 Dec; 4(6):947-55. PubMed ID: 15606325
[TBL] [Abstract][Full Text] [Related]
33. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
34. Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?
Lampropoulou DI; Laschos K; Amylidi AL; Angelaki A; Soupos N; Boumpoucheropoulos S; Papadopoulou E; Nanou E; Zidianakis V; Nasioulas G; Fildissis G; Aravantinos G
J Oncol Pharm Pract; 2020 Apr; 26(3):747-753. PubMed ID: 31382864
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
Ku GY; Haaland BA; de Lima Lopes G
Cancer Chemother Pharmacol; 2012 Aug; 70(2):231-8. PubMed ID: 22699811
[TBL] [Abstract][Full Text] [Related]
36. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
[TBL] [Abstract][Full Text] [Related]
38. Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants.
Raber I; Frazer MB; Zerillo JA; Asnani A
JACC CardioOncol; 2020 Jun; 2(2):329-332. PubMed ID: 34396241
[No Abstract] [Full Text] [Related]
39. The Incidence of Hematological Toxicities in Colorectal Cancer Patients Treated With Fluoropyrimidine-Based Regimens at Princess Noorah Oncology Center.
Khan M; Alharbi S; Aljuhani S; Tunkar M; Morya A; Alnatsheh A; Alshamrani M; Felemban R
Cureus; 2023 Aug; 15(8):e44267. PubMed ID: 37772227
[TBL] [Abstract][Full Text] [Related]
40. Assessing the Hepatotoxic Effects of Fluoropyrimidine Chemotherapy in Male Iraqi Colorectal Cancer Patients.
Challoob MA; Mohammed NS
Cureus; 2024 Apr; 16(4):e58126. PubMed ID: 38741871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
